Theriva Biologics (TOVX) Cash from Financing Activities (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Cash from Financing Activities of $3.9 million for Q1 2026, up 25.85% year-over-year from $3.1 million in Q1 2025, and down 54.29% quarter-over-quarter from $8.5 million in Q4 2025.
Theriva Biologics (TOVX) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Cash from Financing Activities for 16 consecutive years, with $3.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 25.85% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $19.0 million (up 255.7% YoY), while the FY2025 annual figure was $18.2 million, up 231.02% from the prior year.
- Cash from Financing Activities slipped to $3.9 million in Q1 2026 per TOVX's latest filing, from $8.5 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $8.5 million in Q4 2025 and bottomed at -$3.3 million in Q4 2022.
- Historically, Cash from Financing Activities has averaged $1.7 million across 5 years, with a median of $1.1 million in 2023.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities jumped 371500.0% — and 2025, when it plunged 103.98%.
- Theriva Biologics' Cash from Financing Activities stood at -$3.3 million in 2022, then soared by 55.69% to -$1.5 million in 2023, then surged by 100.48% to $7000.0 in 2024, then jumped by 120728.57% to $8.5 million in 2025, then tumbled by 54.29% to $3.9 million in 2026.
- Business Quant data shows TOVX's Cash from Financing Activities at $3.9 million in Q1 2026, $8.5 million in Q4 2025, and -$148000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | -14,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14,000.00 |
| Jun 30, 2026 | -14,000.00 |
| Mar 31, 2026 | 3.87 Mn |
| Mar 31, 2026 | 3.87 Mn |
| Dec 31, 2025 | 8.46 Mn |
| Dec 31, 2025 | 8.46 Mn |
| Sep 30, 2025 | -148,000.00 |
| Sep 30, 2025 | -148,000.00 |
| Jun 30, 2025 | 6.81 Mn |
| Jun 30, 2025 | 6.81 Mn |
| Mar 31, 2025 | 3.07 Mn |
| Mar 31, 2025 | 3.07 Mn |
| Dec 31, 2024 | 7,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Sep 30, 2024 | 3.72 Mn |
| Sep 30, 2024 | 3.72 Mn |
| Dec 31, 2023 | -1.46 Mn |
| Dec 31, 2023 | -1.46 Mn |
| Sep 30, 2023 | 1,000.00 |
| Sep 30, 2023 | 1,000.00 |